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Abstract
A human anti-B antibody of clone BT97 was obtained from a healthy individual of type A of the ABO blood group without
immunization. Cloning was performed by means of heterohybridoma formation of cell fusion between human peripheral
lymphocytes and mouse myeloma cells. The antibody selectively reacted with B-antigen in flow cytometry using red blood cells and
enzyme-linked immunosorbent assay. The VH and VL genes of BT97 were derived from the germline genes of DP-47 and 3p.81A4,
respectively, with a couple of somatic mutational events. Comparative analysis with other reported anti-A, B and H antibodies
revealed that the amino acid sequence of the VH region was more homologous than that of the VL region. The sequence of BT97
showed complete identity with one anti-H natural antibody reported by Marks et al., with the exception of the CDR3 region. It is
not known whether the homologies include the common properties of the natural antibodies; however, a particular germline gene
potentially changes to anti-ABH antibodies. We think that this method is suitable for cDNA preparation of human monoclonal
antibodies to blood group antigens and for sequence analysis.
# 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Carbohydrate complexes combined with proteins and
lipids decorate the plasma membrane of erythrocytes;
moreover, these species are often polymorphic, which is
known as blood types such as ABO, Ii and P type. In the
ABO blood group, ABH antigens, which are carbohy-
drate structures present in many tissues, are synthesized
under the control of highly related genes coding for
glycosyltransferases [1]. The blood type A molecule is
formed by an a1,3GalNAcT corresponding to the A
allele of the ABO locus. The blood type B allele encodes
an a1,3galactosyltransferase that forms the B determi-
nate. O alleles encode functionally inert polypeptides
that do not further modify H-active precursors and
therefore represent null alleles at this locus. Four amino
acid substitutions were identified between A transferase
and B transferase. Most O alleles were found to contain
a single base deletion near the N-terminus of the coding
sequence. The phenotypes A, B, O and AB have been
clinically examined by hemagglutination for transfusion.
The antisera for laboratory examinations were, at one
time, derived from immunized individual donors; how-
ever, these antisera are no longer available as a result of
infectious hazard. To date, monoclonal antibodies
(mAbs) to A and B-antigens raised in mice have
replaced antisera. mAbs are sufficiently effective for
regular laboratory examinations; however, the mAbs are
less valuable than the former human antisera in cases
involving the adsorption-elution test.
Antibodies to ABO antigen-structures are among the
most predominant naturally occurring antibodies. Type
A individuals display anti-B antibodies in their plasma.
Type B individuals exhibit anti-A antibodies. Type O
individuals possess both antibodies. The antibodies are
oligoclonal; additionally, they consist mainly of IgM [2].
Abbreviations: mAb, monoclonal antibody; ELISA, enzyme-linked
immunosorbent assay; RBC, red blood cell; PBL, peripheral blood
lymphocyte; RT-PCR, reverse transcription-polymerase chain
reaction; CDR, complimentarity-determining region.
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Their high titer is maintained throughout the lifespan
following birth despite no apparent specific stimuli. The
physiological importance of natural antibodies remains
unclear; however, roles for natural antibodies including
nonspecific anti-bacterial defense and self-regulation of
the immune system have been proposed [3,4]. Despite
the classical theme, investigations concerning the pro-
duction of specific antibodies by cloned cells display a
number of shortcomings, which may be attributable to
the difficulty associated with the production of human
mAbs.
In order to obtain a human immunoglobulin gene,
two major technical approaches are widely applied. The
first technique involves the phage-display method, often
combined with lymphocyte-transformation by Epstein/
Barr virus (EBV) [5,6]. The second approach consists of
heterohybridoma formation between EBV-transformed
human lymphocytes and mouse myeloma cells [7/9].
However, both methods possess critical limitations. In
the former technique, the combination of H and L-
chains may or may not involve the original species
expressed in the specific antibody producing cells. In
contrast, production of human antibody is quite low
and rapidly diminished under mouse genomic control in
the latter case. However it is certain that the original
combination of H and L-chains is obtained by the fusion
protocol.
In the present study, in order to characterize the
variable region of anti-ABH antibody, the simplest
protocol of the fusion methodology between human
peripheral blood lymphocytes (PBL) and mouse mye-
loma cells was selected [10]. A clone producing anti-B
antibody was obtained. Following determination of the
sequence coding the variable region of the specific
antibody, a comparative analysis was conducted with
those anti-ABH antibodies previously reported.
2. Materials and methods
2.1. Cell fusion
Peripheral blood (100 ml) was extracted from a
healthy volunteer of type A. Mononuclear cells were
isolated by centrifugation on Ficoll-Paque Plus (Amer-
sham Pharmacia Biotech); isolated cells were washed
twice with phosphate-buffered saline (PBS). Mouse
myeloma cells, P3U1, were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum
(FBS) (Morgate) at 37 8C in a saturated atmosphere of
5% CO2. Following harvest, myeloma cells were fused
with human mononuclear cells of 1.2/3.8/108 at a
ratio of 1:10 in a warmed mixture of 1 ml of PEG-1000
(Wako), 1 ml of FBS- free RPMI 1640 and 50 ml of
dimethylsulfoxide. After a 2-min incubation and cen-
trifugation, the pellet was resuspended in 100 ml of
HAT selective medium (Gibco BRL) supplemented with
10% FBS in RPMI 1640 medium. To exclude fibroblast
cells, the cell suspension was placed on 75-cm2 culture
dishes overnight. The fused cells were gently collected
from the dishes, and subsequently transferred into 96-
well culture plates in a volume of 200 ml (2/105 human
cells per well). Following a 1-week incubation, half of
the supernatant was discarded from each well and an
identical volume of HT medium was added. After 4
weeks, the supernatants were screened by flow cytome-
try analysis with red blood cells (RBCs) and enzyme-
linked immunosorbent assay (ELISA).
2.2. Flow cytometry analysis
RBCs of types A, B and O were prepared using
peripheral blood extracted from healthy volunteers. The
culture supernatant was incubated with 5 ml of the 3%
RBC suspensions for 1 h. After washing twice with PBS,
the RBCs were incubated with a 100-fold dilution of
FITC-conjugated goat anti-human IgM (m) (Kirkegaard
& Perry Laboratories) for 1 h. The reactions were
performed at room temperature. Following additional
washing and fixation with 0.25% para-formaldehyde in
PBS, cells were analyzed with a FACS Calibur (Becton
Dickinson) flow cytometry device.
2.3. ELISA
A-and B-tri-oligosaccharides conjugated to human
serum albumin (IsoSep AB) were independently coated
onto microtiter plates (Sumitomo Bakelite) at 1 mg/ml
for 1 h. After blocking with 0.3% gelatin, the plates were
incubated with the culture supernatant for 1 h. Follow-
ing washing with 0.05% Tween 20 in PBS, the plates
were incubated with rabbit antibodies to human IgM,
IgG, l light chain and k light chain (Dako) for 1 h,
followed by peroxidase-conjugated goat F(ab?)2 to
rabbit IgG (Medical & Biological Laboratories) for 1
h. Following subsequent washing, the enzymatic reac-
tion was conducted with a substrate solution consisting
of 0.55 mg/ml 2,2?-azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid) and 0.03% H2O2. The optical density was
measured at 405 nm with an auto-plate reader. These
reactions were performed with a volume of 50 ml at
room temperature.
2.4. Isolation of the variable regions of immunoglobulin
cDNA
Total RNA was prepared from the heterohybridoma
cells employing a RNeasy mini kit (Qiagen). The initial
strand cDNA was synthesized by AVM-reverse tran-
scriptase (Takara) via priming nine random oligomers
and oligo-dT. In order to amplify Fab portions, PCR
amplification was effected with oligonucleotide mixtures
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of VL/CL for k and l chains and of VH/CH1 for m and
g chains. Primers were designed according to those
reported by Takekoshi et al. with minor modifications
[11]. The reaction progressed with HotStar Taq poly-
merase (Qiagen). Reaction conditions were as follows:
the initial denaturation step occurred at 95 8C for 15
min, followed by 35 rounds of a temperature cycle at
95 8C for 30 s, 55 8C for 30 s and 72 8C for 1 min.
Following electrophoresis on 1% agarose gels, PCR
products were purified from the excised pieces utilizing a
spin column (Gibco BRL). DNA fragments were sub-
cloned into a plasmid vector, p123T (Mo Bi Tec);
subsequently, DNA fragments were labeled with
the BigDye terminator cycle sequencing kit and ana-
lyzed with the ABI prism 310 auto-sequencer (Perkin/
Elmer).
2.5. Sequence analysis
Nucleotide sequences of anti-ABH antibodies, re-
trieved from the DDBJ/EMBL/GenBank database,
include the following accession numbers: ABO.B1-
VH/Z23026; ABO.B1-VL/Z23027, ABO.HI1-
VH/Z23028; ABO.HI1-VL/Z23029; HuA-VH/
L41175; HuA-VL/L41174. Nucleotide sequences of
A-fAb and B-fAb were provided by Dr Curiel-Ques-
ada [12]. The sequence of FB5.7 was provided by Dr
Siegel [13]. To characterize the nucleotide sequence of
the positive clones, a database search was conducted of
the IMGT (http://imgt.cines.fr:8104/home.html) [14], V-
BASE (http://www.mrc-cpe.cam.ac.uk/) and DDBJ/
EMBL/GenBank (http://www.ddbj.nig.ac.jp/) data-
bases. Multiple alignments were effected employing the
CLUSTAL W program, ver. 1.60 [15]. Results were
illustrated with MACBOXSHADE, ver. 2.11. The amino
acid identity (%), designated to be the identical
amino acid number by the number of total regions
except for gaps, was calculated using the MACBOXSHADE
program.
3. Results
3.1. Cloning of human anti-B mAb
In order to obtain human antibodies to ABH antigens
mAb, heterohybridomas between human PBL and
mouse myeloma cells, P3U1, were generated according
to the common procedure. Pre-culture in the dishes was
effective with respect to removal of excessive fibroblasts.
Hybridoma colonies were observed in 16/38% of the
culture plates 4 weeks later. This observation indicated
that the lymphocytes were successfully fused at a
frequency of approximately 4/107. Flow cytometry
analysis and ELISA were conducted to clone the
hybridoma cells and to evaluate the antibodies to
ABH antigens. Hemagglutination was not readily ap-
parent even in the presence of the Coombs reagent. As
displayed in Fig. 1, the presence of specific antibodies
was evident based on flow cytometry using RBCs. When
the supernatant from all wells containing colonies was
examined by flow cytometry analysis, three positive
clones were obtained, which secreted antibodies reactive
with B-RBCs. After a single step of limiting dilution,
one cloned hybridoma cell line was obtained, which was
designated BT97. The BT97 cells maintained antibody
production for approximately 10 weeks after fusion. To
ensure specificity and to determine the subclass, ELISA
was conducted employing soluble antigen coated plates
(Fig. 2). BT97 mAb selectively reacted with the B-
antigen as well. In addition, ELISA with subclass-
specific second antibodies demonstrated that the BT97
mAb was comprised of Hm and Ll chains; moreover,
the whole serum of the donor also contained anti-B
antibodies composed of Hm and Ll chains.
Fig. 1. Flow cytometry analysis using B-RBC (upper) and A-RBC
(lower) to detect positive hybridoma clones. The shadowed area
represents the peaks stained with the supernatant of BT97. Bold line
represents the peaks stained with human anti-A antiserum to B-RBC
and anti-B to A-RBC as a control. Thin line depicts the peaks stained
in the absence of the first antibody as a negative control.
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3.2. Sequence analysis of BT97 mAb
To deduce amino acid sequence of variable regions,
reverse transcription-polymerase chain reaction (RT-
PCR) was performed on the RNA extract from the
BT97 cells during production of the antibody. PCR
products were subcloned into a vector, followed by
complete sequencing from both strands. The nucleotide
sequence of H and L-chain variable regions of the BT97
mAb are deposited in DDBJ/EMBL/GenBank data
bank (accession numbers AB087877 and AB087878,
respectively). The sequence of BT97 mAb was compara-
tively analyzed against several human mAbs to ABH
antigens that have been reported. B-fAb [12], ABO.B1
[16] and FB5.7 [13] are anti-B antibodies, A-fAb [12]
and HuA [17] are anti-A antibodies, and ABO.HI1 [16]
is an anti-HI antibody. Five of the six reported anti-
ABH antibodies were obtained employing the phage-
display method. The remaining HuA was produced by
cloned EBV-transformed lymphocytes that were stabi-
lized by fusion with a human/mouse hybridoma [18].
In a fashion similar to BT97 mAb, five of the six anti-
ABH antibodies, B-fAb, ABO.B1, A-fAb, HuA and
ABO.HI1, were comprised of Hm chains; the remaining
FB5.7 mAb demonstrated an Hg chain. The VH genes
of BT97, B-fAb, ABO.B1, HuA, and ABO.HI1, belong
to IGHV3 in the IMGT classification, whereas the other
two genes of FB5.7 and A-fAb belong to IGHV4. In
contrast, the VL and JL genes of these species exhibited
a variety of the IGLV and IGLJ groups.
Based on their homology, it was evident that the VH
and VL genes of BT97 were derived from the germline
DP-47 gene [19] corresponding to the IGHV3 subgroup
in the IMGT database, and the germline 3p.81A4 [20]
corresponding to the IGLV3-10 subgroup, respectively.
ABO.B1 and ABO.HI1 were also derived from the DP-
47 gene. B-fAb and HuA were derived from the DP-46
gene. Additionally, FB5.7 and A-fAb were derived
from the DP-70 and DP-67 genes, respectively. Fig. 3
shows the multiple alignment along the VH and VL
regions among the eight anti-ABH mAbs including
BT97 and its germlines. It was clear that the VH genes
revealed high homology, with the exception of the third
complimentarity-determining region (CDR3). In con-
trast, the VL genes displayed less homology than that of
the VH genes. Employing this multiple alignment, the
amino acid sequence identity (%) of the CDR and the
framework (FR) regions in the VH and VL genes of
BT97 to the germline and the six antibodies was
calculated (Table 1). Germline sequences (DP-47 and
3p.81A4) did not completely include the CDR3 region
and its downstream regions; thus, the estimation of the
identity of the CDR3 region was relatively low. The VH
gene of BT97 and DP-47 are identical, with the
exception of a three-nucleotide difference in the region
of the 5? primer used in PCR. Thus, the differences
between the VH gene of BT97 and DP-47 in the FR1
region had potentially been introduced by mismatches
during the PCR priming cycles. The VL gene of BT97
differs from 3p.81A4 by seven nucleotides, which are
accompanied by two amino acid substitutions in the
CDR3 region. Except for these differences, the VH and
VL genes of BT97 exhibited no other substitution in
their nucleotide sequences. With respect to the FR
regions of the VH gene of anti-ABH antibodies, high
homology was evident with 53/100% residual identities.
Particularly, BT97 and ABO.HI1 possessed identical
sequences in the VH gene except for the CDR3 region
downward. On the other hand, FR regions of the VL
gene displayed identities of 35/78%.
4. Discussion
We obtained a human mAb of BT97 that reacted with
B-antigen of the ABO blood group. Heterohybridoma
formation in this study is characterized by methodolo-
gical limitations, including low fusion rate and unstable
antibody production. Large volumes of the antibody-
containing supernatant were not obtained; however, it
was sufficiently effective to clone the cells and to prepare
cDNA coding the specific antibody. Although this
protocol is in need of improvement, the advantage
that the combination of the obtained H and L-chains
is original indicates that this approach is suitable for the
analysis of the sequence of immunoglobulins.
As screening procedures, hemagglutination and
ELISA are common in preparation of anti-RBC anti-
bodies [12,13,16,17]. In this series of experiments,
hemagglutination was rarely observed with the culture
Fig. 2. Recognition of A and B antigens by the antibody of the BT97
clone supernatant and the donor antiserum. The microtiter plates were
coated with B-tri-oligosaccharides. The O.D. value is expressed as the
mean9/SD.
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Fig. 3. The multiple alignment of the amino acid sequence of the H and L-chains. Amino acids are designated by single-letter code. Amino acids
identical to BT97 are shown on a black background; amino acids similar to BT97 are highlighted with a gray background. The CDR and FR regions
defined by the IMGT database are indicated over the top; those defined by the V-BASE are in parenthesis at the bottom.
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supernatant, which may be attributable to a low
concentration of the antibody. In addition, ELISA,
utilizing plates coated by the artificially synthesized
soluble antigens, was not able to determine whether the
obtained values precisely reflected the actual interaction
of the antibody to RBCs. For these reasons, analysis by
flow cytometry has been established in our trial. Flow
cytometry employing RBCs was more sensitive and
demonstrative than was hemagglutination.
The nucleotide sequence of the variable regions of the
BT97 mAb was determined by RT-PCR; moreover, the
H and L-chains were derived from the DP-47 and
3p.81A4 germline genes, respectively. Both the VH
and VL genes shared high amino acid identities of 97
and 98%, respectively, with their corresponding germ-
line genes. These genes appeared to contain a minimum
number of somatic mutational events, suggesting that a
germline gene such as DP-47 might originally have an
affinity to ABH antigens. It has been repeatedly
suggested that fetal antibodies and auto-antibodies are
dominated by rarely mutated or unmutated germline
VH genes and that these antibodies are often polyreac-
tive [21/24]. We think that the antibodies to ABH-
antigens appear to be naturally occurring in the
repertoire of germline genes.
In an attempt to evaluate the amino acid sequence
and its organization of the BT97 mAb, a comparative
analysis was performed with the six reported anti-ABH
antibodies. Among these anti-ABH antibodies, the
amino acid sequence of the H-chains exhibited greater
homology than that displayed by the L-chains. The
human mAbs of B-fAb, FB5.7, A-fAb and HuA were
obtained from immune disease patients. ABO.B1 and
ABO.HI1 were acquired from a normal human; how-
ever, Siegel et al. notes that the donor for ABO.B1 was
immunized [25]. Therefore, only two mAbs of BT97 and
ABO.HI1 are naturally occurring mAbs. Of particular
interest, the VH region of BT97 showed the highest
homology with ABO.HI1, with the exception of the
CDR3 region. As for natural anti-ABH antibodies, the
reactive species are possibly derived from the same
germline genes. Furthermore, since BT97 is anti-B and
ABO.HI1 is anti-HI, the differences in the CDR3 of the
VH region or the VL region may distinguish the antigen
structures. Anti-B mAb of B-fAb also exhibited high
homology to BT97 with the complete identities in the
CDR1 and FR3 regions of the VH gene. In contrast,
FB5.7 revealed the lowest homology in the VH region
with BT97, particularly of the CDRs, which should be
caused by the step of affinity maturation.
In conclusion, we obtained human anti-B mAb,
BT97, via human/mouse heterohybridoma formation.
Comparative sequence analysis of variable regions was
performed with previously reported species. Strong
homology, particularly in CDRs of the H chain, was
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general occurrence of natural antibodies in the ABO
blood group, whereas the ternary structure of the
specific antibodies should be constrained for the carbo-
hydrates of antigen. In the future, further accumulation
of data regarding the sequence of specific antibody
repertoire will be necessary in order to draw a conclu-
sion. Experiments involving targeted mutagenesis are
also required to identify the antigen-reactive site on
antibodies.
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